Prophylactic Effect of Nirmatrelvir/Ritonavir and Ursodeoxycholic Acid on Reducing Complications After Cardiac Surgery
Status:
Recruiting
Trial end date:
2026-01-06
Target enrollment:
Participant gender:
Summary
Prophylactic effect of nirmatrelvir/ritonavir and ursodeoxycholic acid on reducing
complications after cardiac surgery during covid-19 pandemics (the pep trial) is a
multicenter, randomized controlled trial. The aim of the pep trial is to investigate whether
prophylactic use of nirmatrelvir/ritonavir and ursodeoxycholic could reduce complications
after cardiac surgery.